通过系统结构-活性优化发现新型和强大的哈林顿因衍生物P2:半合成,抗白血病活性和机制研究研究
Zhongli Xu1, Shuting Shen2, Xinyu Ding2
1Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai, 201210, China.
European journal of medicinal chemistry
|January 8, 2026
概括
研究人员开发了新的哈林顿因衍生物来对抗白血病. 一种新的化合物P2通过抑制蛋白质合成显著增强了抗白血病功效,并提供了一个有前途的治疗候选者.
科学领域:
- 药用化学 医学化学
- 药理学 药理学是指药理学的学科.
- 有机合成 有机合成
背景情况:
- 来自Cephalotaxus物种的哈林顿因衍生物对白血病表现出抗增殖作用.
- 有限的结构-活性关系 (SAR) 研究存在于哈林顿因衍生.
研究的目的:
- 合成一个多样化的哈林顿因衍生物库.
- 进行全面的SAR研究,探索不同位置的修改.
- 确定具有增强抗白血病活性的新衍生物.
主要方法:
- 核性环氧环开放反应与素,亚酸和硫核.
- 在侧链 (1'-5') 和脑毒素核心 (位置2) 上探索SAR.
- 在体外抗增殖试验,蛋白质合成抑制研究和分子对接.
主要成果:
- 构建了一个多样化的哈林顿因衍生物库.
- 代谢不稳定的4'-基组被以或基基组成功取代.
- 新型衍生品P2与同型哈林顿因 (HHT) 相比,对白血病细胞系的功效增加了约10倍.
- P2 抑制了蛋白质合成,降低了关键的生存蛋白质,如c-Myc和Mcl-1.
- 分子对接揭示了在核糖体内P2的独特和稳定的结合模式.
结论:
- 这些发现为未来的哈林顿因导数优化提供了洞察力.
- 通过抑制蛋白质合成,P2表现出强大的抗白血病作用.
- P2是一种有前途的抗白血病候选药物,需要进一步开发.
相关概念视频
Structure-Activity Relationships and Drug Design
1.7K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.7K
Drug Discovery: Overview
10.9K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
10.9K
Adrenergic Agonists: Chemistry and Structure-Activity Relationship
3.8K
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
3.8K


